Particle.news
Download on the App Store
6 ARTICLES
·
last wk.

White House Secures Deals With Nine More Drugmakers, Bringing Price‑Cut Pact to 14 of 17 Targets

In exchange for three years of tariff relief, companies commit to MFN Medicaid pricing, deep TrumpRx.gov cash discounts and a pledged $150 billion in U.S. investment.

Donald Trump departs after delivering remarks on lowering prescription drug prices at an event in the Roosevelt Room of the White House on December 19, 2025, in Washington, D.C.
Image
Pharmacist recommends medicines to customers. Asking the questions of medication. Professional Asian male pharmacist giving prescription medications to female patient customers at drugstore shelves.
Image

Overview

  • Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novartis and Sanofi joined earlier signers, lifting participation to 14 of 17 manufacturers approached by the administration.
  • The framework sets most‑favored‑nation pricing for state Medicaid and requires listing select medicines for steep direct‑to‑consumer discounts on TrumpRx.gov, with new drugs launching at prices no higher than in other wealthy countries.
  • Merck will sell Januvia and Janumet at roughly 70% off list prices for cash buyers, and Bristol Myers Squibb will provide Eliquis free to Medicaid beginning Jan. 1, 2026, alongside other discounted offerings.
  • The agreements include a three‑year exemption from drug tariffs and collective pledges exceeding $150 billion for U.S. manufacturing and R&D, plus donations to a strategic API reserve and emergency conversion of ingredients into finished drugs.
  • Officials said TrumpRx.gov will begin offering deals early next year and will exclude provider‑administered injectables, while the remaining firms—Regeneron, Johnson & Johnson and AbbVie—are expected to finalize agreements next week as experts debate how much insured patients will benefit given PBM practices.